| 翻訳と辞書 |
| Kadmus Pharmaceuticals, Inc. ： ウィキペディア英語版 |
Organon International
Organon was a pharmaceutical company headquartered in Oss, Netherlands. In November 2007, Schering-Plough Corporation, based in New Jersey, USA, acquired Organon, active pharmaceutical ingredient producer Diosynth (separate from Organon until 2004), and its veterinary pharmaceutical sister company Intervet from Akzo Nobel. In November 2009, Schering-Plough merged with Merck & Co. under the name Merck & Co., known as Merck Sharp & Dohme or MSD outside the United States and Canada.
Organon deals in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, HRT and anesthesia. Organon sells to international markets.
In Oct. 16, 2014 USA government charged this drug manufacturer due to improper financial incentives (kicksbacks) to nursing homes for market-shares discounts to encourage the use of Remeron and also for misrepresentation of drug prices. Organon paid 622,350 in restitution for Federal Anti-Kickback Statute.
==History==
Organon was founded by Dr. Saal van Zwanenberg in Oss, the Netherlands, in 1923 as Zwanenberg-Organon. Its first product was insulin in 1923. In the thirties it manufactured estrogens.〔 In 1948, Organon acquired the Newhouse research site in Scotland, United Kingdom. The production of cortisone was initiated in 1953.〔 The now named Koninklijke Zwanenberg-Organon (KZO) fused with the fibre producer AKU in 1969 to become AKZO, later Akzo Nobel. Organon was the human health care business unit of Akzo Nobel and transferred its headquarters to New Jersey, USA〔(【引用サイトリンク】url=http://www.aei.org/files/2003/03/18/20030318_Calfee.pdf )〕 while the main headquarters of Akzo Nobel remained in Arnhem, and has since moved to Amsterdam. Manufacturing facilities are in the Netherlands, Germany, the United Kingdom, Ireland, China, Japan, and the USA.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Organon International」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|